VIR Estadísticas clave
Alto
9.09
Abrir
8.82
Volumen
1.68M
Bajo
8.77
Cierre anterior
8.69
Valor negociado
14.99M
Máx. 52 sem.
11.66
Volumen rel.
1.022
Amplitud (%)
3.62%
Mín. 52 sem.
4.16
Tasa de rotación
1.00%
Cap. de Mercado
1.46B
PER (TTM)
--
PER (Anual)
2.234
P/B
1.8
P/S
22.38
Beneficio por acción (BPA)
-3.137
Dividendo (TTM)
0
Rentabilidad por dividendo
0.00%
Acciones en circulación
168.65M
Moneda
USD
VIR Rendimiento del Precio
7 día
30 día
90 día
180 día
En lo que va del año
1 Año
VIR Distribución del flujo de dinero
VIR Volumen diario de ventas en corto
VIR Historial de short interest
Resumen de la acción VIR
As of 2026-07-28, the Vir Biotechnology, Inc. (VIR) stock price today is 8.8. Based on this price, the company has a market capitalization of $1.46B, with a P/E ratio of --.
On 2026-07-28, VIR traded between 8.77 and 9.09. Today’s stock price is 0.34% above the daily low and 3.19% below the daily high, placing VIR dekat dari la parte inferior de its most recent trading range.
Trading volume currently stands at 1.68M, compared with an average daily volume of 1.65M. This suggests that trading activity is aproximadamente en línea con su nivel habitual than usual.
Over the past year, Vir Biotechnology, Inc. shares have traded between 4.16 and 11.66. At today’s price, VIR is 111.54% above its 52-week low and 24.53% below its 52-week high.
VIR Noticias relacionadas
Acerca de VIR
Nombre empresa
Vir Biotechnology, Inc.
Sector
Health Technology
Industria
Biotechnology
Intercambios
Nasdaq
Número de empleados
367
Tamaño del lote
100
Sitio oficial
Moneda
USD
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Related Stocks
VIR FAQ
© 2026 CoinGlass, all rights reserved
